Head-to-head evidence
AADvac1 vs ACI-35.030
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
AADvac1
Developed by Axon Neuroscience
NCT02579252 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 208 participants, with safety as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: August 2028 · NCT07167966 (registry estimate)
ACI-35.030
Developed by AC Immune and partners
NCT04445831 · Phase 1/2 · completed
This was a randomized, quadruple-blinded, placebo-controlled study, which is a strong design foundation, but the enrollment was very small (57 participants split across seven arms, several with only 4-6 subjects), and the primary endpoints were safety/tolerability counts and antibody-titer levels rather than a hard clinical or cognitive outcome - cognitive and functional scales (CDR-SB, RBANS, NPI) were only exploratory and their results were not even posted. Because the primary comparisons here are immunogenicity/safety readouts rather than a statistically tested clinical efficacy endpoint, this evidence is real but limited.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AADvac1's landscape · ACI-35.030's landscape